Leelyn Smith’s VanEck Biotech ETF BBH Stock Holding History

Leelyn Smith’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-627	Closed	-$87	–	323
2019 Q4	$87	Buy	+627	New	+$82.4K	0.04%	164

Other funds holding BBH

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

BRM

Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return

Leelyn Smith's BBH Position: Q1 2020 in Review

Leelyn Smith sold out of VanEck Biotech ETF (BBH) in Q1 2020, closing a stake of 627 shares — an estimated $87 sold.

Leelyn Smith first reported a position in BBH in Q4 2019 and held it in 1 quarter. The position peaked at $87 in Q4 2019. 83 funds tracked by Wall St. Rank hold BBH as of Q1 2020.

Leelyn Smith reported no remaining VanEck Biotech ETF position as of Q1 2020 after selling out during the quarter.
Leelyn Smith sold 627 VanEck Biotech ETF shares in Q1 2020, an estimated $87.
Leelyn Smith first reported a position in VanEck Biotech ETF in Q4 2019 and held it in 1 quarter.
Leelyn Smith's VanEck Biotech ETF position peaked at $87 in Q4 2019.
83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2020.

Based on Leelyn Smith's 13F filing for Q1 2020, filed 6 May 2020.